India, June 23 -- Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and Galectin Therapeutics, which has reached an agreement with the FDA on key elements of its planned Phase 3 MASH program, among others.
Read on.
Boundless Bio Makes a Bold Move with Serapha Merger
Boundless Bio Inc. (BOLD) has agreed to combine with privately held Serapha Bio, Inc in an all-stock merger. Before the closing, Boundless Bio expects to declare a cash dividend to pre-merger Boundless stockholders.
The transaction is expected to close in the fourth quarter of 2026.
Following completion...